Sonoma Pharmaceuticals, Inc. (SNOA): Price and Financial Metrics


Sonoma Pharmaceuticals, Inc. (SNOA): $3.03

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SNOA POWR Grades


  • Value is the dimension where SNOA ranks best; there it ranks ahead of 67.91% of US stocks.
  • The strongest trend for SNOA is in Growth, which has been heading down over the past 119 days.
  • SNOA ranks lowest in Momentum; there it ranks in the 9th percentile.

SNOA Stock Summary

  • SNOA has a higher market value than only 0.87% of US stocks; more precisely, its current market capitalization is $10,408,185.
  • Revenue growth over the past 12 months for Sonoma Pharmaceuticals Inc comes in at -40.68%, a number that bests only 4.18% of the US stocks we're tracking.
  • Sonoma Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -69.67%, greater than the shareholder yield of only 6.02% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sonoma Pharmaceuticals Inc are TORM, VRME, NAOV, AOUT, and UTMD.
  • SNOA's SEC filings can be seen here. And to visit Sonoma Pharmaceuticals Inc's official web site, go to www.sonomapharma.com.

SNOA Valuation Summary

  • In comparison to the median Healthcare stock, SNOA's price/sales ratio is 78.95% lower, now standing at 0.8.
  • SNOA's price/sales ratio has moved down 20.2 over the prior 177 months.
  • Over the past 177 months, SNOA's EV/EBIT ratio has gone up 2.

Below are key valuation metrics over time for SNOA.

Stock Date P/S P/B P/E EV/EBIT
SNOA 2021-08-31 0.8 2.9 -2.5 -2.8
SNOA 2021-08-30 0.7 2.7 -2.3 -2.6
SNOA 2021-08-27 0.8 2.7 -2.4 -2.7
SNOA 2021-08-26 0.7 2.6 -2.3 -2.6
SNOA 2021-08-25 0.7 2.7 -2.3 -2.6
SNOA 2021-08-24 0.7 2.7 -2.3 -2.6

SNOA Growth Metrics

    Its 5 year price growth rate is now at -84.27%.
  • Its year over year revenue growth rate is now at -1.62%.
  • The 2 year cash and equivalents growth rate now stands at -63.33%.
SNOA's revenue has moved down $2,597,000 over the prior 70 months.

The table below shows SNOA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 12.487 -4.329 -5.802
2021-09-30 14.521 -3.257 -5.508
2021-06-30 16.546 -2.31 -5.288
2021-03-31 18.629 -3.378 -3.95
2020-12-31 21.051 -5.493 -1.664
2020-09-30 20.793 -7.079 -2.098

SNOA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SNOA has a Quality Grade of D, ranking ahead of 19.4% of graded US stocks.
  • SNOA's asset turnover comes in at 1.011 -- ranking 24th of 682 Pharmaceutical Products stocks.
  • AGLE, REGN, and NAVB are the stocks whose asset turnover ratios are most correlated with SNOA.

The table below shows SNOA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.011 0.348 -0.457
2021-03-31 1.064 0.352 -0.307
2020-12-31 1.210 0.393 -0.153
2020-09-30 1.226 0.405 -0.202
2020-06-30 1.214 0.411 -0.353
2020-06-30 1.305 0.416 -0.272

SNOA Stock Price Chart Interactive Chart >

Price chart for SNOA

SNOA Price/Volume Stats

Current price $3.03 52-week high $13.36
Prev. close $3.03 52-week low $2.55
Day low $2.97 Volume 7,200
Day high $3.11 Avg. volume 623,339
50-day MA $3.18 Dividend yield N/A
200-day MA $4.18 Market Cap 9.39M

Sonoma Pharmaceuticals, Inc. (SNOA) Company Bio


Sonoma Pharmaceuticals, Inc. operates as a pharmaceutical company. The Company develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. Sonoma Pharmaceuticals serves customers worldwide.


SNOA Latest News Stream


Event/Time News Detail
Loading, please wait...

SNOA Latest Social Stream


Loading social stream, please wait...

View Full SNOA Social Stream

Latest SNOA News From Around the Web

Below are the latest news stories about Sonoma Pharmaceuticals Inc that investors may wish to consider to help them evaluate SNOA as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | March 24, 2022

Sonoma Pharmaceuticals Reports Third Quarter FY 2022 Financial Results

WOODSTOCK, Ga., February 11, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its third fiscal quarter and nine months ended December 31, 2021.

Yahoo | February 11, 2022

HBC Financial Services, PLLC Buys Apollo Investment Corp, Lockheed Martin Corp, Airbnb Inc, ...

Investment company HBC Financial Services, PLLC (Current Portfolio) buys Apollo Investment Corp, Lockheed Martin Corp, Airbnb Inc, Deere, Sonoma Pharmaceuticals Inc, sells Apple Inc, Lowe's Inc, PayPal Holdings Inc, Waste Management Inc, Cleanspark Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HBC Financial Services, PLLC.

Yahoo | January 28, 2022

Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China

WOODSTOCK, Ga., January 20, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has added Salus Medical as an additional distribution partner in the United States for dental care and expanded its oral and dental care li

Yahoo | January 20, 2022

Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022

WOODSTOCK, Ga., January 05, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions, today announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The conference is being held on January 10-13, 2022 virtually.

Yahoo | January 5, 2022

Read More 'SNOA' Stories Here

SNOA Price Returns

1-mo N/A
3-mo -24.44%
6-mo -33.55%
1-year -60.13%
3-year -61.75%
5-year -94.91%
YTD -33.55%
2021 -37.19%
2020 66.51%
2019 -31.77%
2018 -86.97%
2017 8.13%

Continue Researching SNOA

Want to see what other sources are saying about Sonoma Pharmaceuticals Inc's financials and stock price? Try the links below:

Sonoma Pharmaceuticals Inc (SNOA) Stock Price | Nasdaq
Sonoma Pharmaceuticals Inc (SNOA) Stock Quote, History and News - Yahoo Finance
Sonoma Pharmaceuticals Inc (SNOA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6443 seconds.